53 results about "CD30" patented technology

The invention discloses a bispecific antibody which comprises a first protein functional region targeting CD30 and a second protein functional region targeting CD16a, the first protein functional region comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3. The invention also discloses nucleic acid for coding the antibody, a recombinant expression vector, a transformant, a preparation method of the antibody, an antibody drug conjugate, a pharmaceutical composition or a kit containing the antibody drug conjugate, and applications of the nucleic acid, the recombinant expression vector and the transformant in preparation of drugs for preventing and / or treating tumors. The bispecific antibody provided by the invention can effectively activate the NK cells and can effectively target human tumor cell related antigen CD30 protein, mediate the killing activity of the NK cells to target cells, and induce and further enhance the tumor inhibition effect of the NK cells to tumor cells.

The present invention inter alia relates to a chimeric transmembrane receptor comprising a polypeptide, wherein the polypeptide comprises at least one T cell immunoreceptor with Ig and ITIM domains (TIGIT) polypeptide region comprising a TIGIT extracellular ligand binding domain; further wherein the polypeptide comprises at least one non-TIGIT polypeptide region, wherein the at least one non-TIGIT polypeptide region comprises a transmembrane polypeptide region of CD2, CD40, HVEM, or CD30, and wherein the at least one non-TIGIT polypeptide region comprises at least one costimulatory cytoplasmic polypeptide domain, region or motif of CD2, CD40, HVEM, or CD30, or wherein the transmembrane domain is from TIGIT and further wherein the at least one non-TIGIT polypeptide region comprises at least one costimulatory cytoplasmic polypeptide domain, region or motif of CD2 or CD28. The invention also relates to corresponding nucleic acids, vectors and T-cells comprising or expressing the chimeric receptors, to a pharmaceutical composition comprising the T-cells, and to methods for preparing a T-cell for immunotherapy and for treating a disease, respectively, wherein the chimeric transmembrane receptor is used.

The present invention provides novel antibodies and antigen binding fragments thereof that bind to human CD30. Also presented are single chain variable antibodies, chimeric antigen receptors and uses thereof. Methods of treating cancer are also disclosed.

The present application provides an anti-human CD153 monoclonal antibody that specifically binds to human CD153 and inhibits an intermolecular interaction between human CD153 and CD30, or a binding fragment thereof. The present application also provides: a chimeric antigen receptor including an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the extracellular antigen binding domain has the same heavy-chain hypervariable region and the same light-chain hypervariable region as those in the monoclonal antibody according to the present application; and a CAR-T cell capable of expressing the chimeric antigen receptor. The monoclonal antibody and the binding fragment thereof and the CAR-T cell according to the present application are useful for the treatment or prevention of diseases associated with CD153, such as multiple sclerosis.

The present invention provides novel bispecific antibodies that bind to human CD30 and uses thereof. Methods of treating cancer using the bispecific antibodies described herein are also provided.

The present invention provides a non-human animal expressing human or chimeric (e.g., humanized) CD30L and / or CD30 proteins and methods of use thereof.

The invention relates to a gene-edited cytotoxic cell comprising a chimeric antigen receptor (CAR) that binds CD30, for use in the treatment of an infection, in which infected cells express CD30. In embodiments, the treatment comprises the cytotoxic cell binding to a human target cell, which is infected with a chronic inflammatory virus and expresses CD30. In embodiments, the treatment comprises cytotoxic activity against a reservoir of infected human CD30-expressing target cells in a subject with a chronic viral infection with associated pathologies, immune dysregulations and autoimmune diseases. Corresponding medical uses and methods of treatment are encompassed by the present invention. In another aspect, the invention relates to the CD30-CAR-expressing gene-edited cytotoxic cell as described herein. In other aspects, the invention relates to the CD30-CAR nucleic acid construct and the CAR polypeptide as described herein.

The present disclosure relates to expanding and production of gamma delta (γδ) T cells, e.g., Vδ1+ γδ T cells. In particular, the present disclosure provides improved methods and processes for activating and expanding γδ T cells (e.g., Vδ1+ γδ T cells) using combined CD3 and CD30 agonists and cytokines.

The invention discloses a multiplex fluorescence immunohistochemical detection kit for rare lymphoma and application of the multiplex fluorescence immunohistochemical detection kit. The multiplex fluorescence immunohistochemical detection kit for rare lymphoma comprises a primary antibody reagent and a fluorescence staining reagent, the primary antibody reagent is prepared from a rabbit anti-human CD15 monoclonal antibody, a rabbit anti-human CD30 monoclonal antibody, a KI-67 monoclonal antibody, a rabbit anti-human CD79b monoclonal antibody, a rabbit anti-human CD3 monoclonal antibody and a rabbit anti-human CD20 monoclonal antibody. When the multiplex fluorescence immunohistochemical detection kit for the rare lymphoma is used, a false positive result caused by channel spectrum crosstalk is avoided to the greatest extent through a specific staining sequence of each target protein and fluorescein matching, and the purpose of detecting the rare lymphoma, especially the rare type of lymphoma, is achieved. The kit can be used for synchronous detection of lymphoma, such as hodgkin lymphoma, mantle cell lymphoma and marginal region lymphoma, and provides a reliable basis for lymphoma immune targeted therapy.

A recombinant natural killer (NK)-92 cell transfected with a nucleic acid and gamma (γ) irradiated, wherein the nucleic acid encodes: a homing receptor and / or cytokine; an antigen binding protein or c

Provided herein are antibody-drug conjugates that bind to CD30 comprising an anti-CD30 antibody or an antigen-binding fragment thereof and methods of using the same to treat cancer in a subject.

Provided herein are antibody-drug conjugates that bind to CD30 comprising an anti-CD30 antibody or an antigen-binding fragment thereof and methods of using the same to treat cancer in a subject.

The present application relates to a kind of chimeric antigen receptors comprising costimulatory receptors, the structure of the chimeric antigen receptor is scFv (X)-(Y) CD3 zeta-2A-(Z);Wherein, X includes tumor targeting antibody or can be combined with tumor specific ligand, receptor;Y is the intracellular region of costimulatory receptor, Z is costimulatory receptor, the costimulatory receptor is selected from ICOS, CD28, CD27, HVEM, LIGHT, CD40L, 4-1BB, OX40, DR3, GITR, CD30, TIM1, SLAM, CD2, CD226.The present application also provides a kind of CAR-T cell constructed by the recombinant expression vector of the above-mentioned chimeric antigen receptor and its preparation method and application.The CAR-T cell described in the present application significantly improves the tumor killing ability and expansion capacity.

The invention relates to a humanized CD30 antibody, a CD30 CAR-T cell and application of the humanized CD30 antibody and the CD30 CAR-T cell. Specifically, the present invention provides a humanized antibody targeting CD30, a chimeric antigen receptor (CAR) fusion protein comprising a humanized antigen binding domain targeting CD30, and an engineered immune cell (e.g., a CAR-T cell) expressing the CAR fusion protein. The CAR-T cell disclosed by the invention has relatively high affinity and biological activity, relatively good amplification performance and relatively good in-vitro and in-vivo anti-tumor effects.

The invention relates to an anti-CD30 nano antibody as well as a preparation method and application thereof. The anti-CD30 nano antibody is obtained through a phage display technology. The method disclosed by the invention is simple and quick to operate; and a mammalian cell expression system induces high-efficiency expression of the antibody, and the activity of the antibody is closer to that of a natural antibody. The anti-CD30 nano antibody which is specifically combined with the Human CD30 is obtained through enzyme-linked immuno sorbent assay (ELISA) and FACS detection.

This invention provides a method for screening peptides that specifically target T cells, comprising providing T cells having a subset selected from CD1, CD2, CD3, CD4, CD5, CD7, CD8, CD16, CD25, CD26, CD27, CD28, CD30, CD38, CD39, CD40L, CD44, CD45, CD62L, CD69, CD73, CD80, CD83, CD86, CD95, CD103, CD119, CD126, CD150, CD152 (CTLA-4), CD153, CD154 (CD40L) The T cells are labeled with at least one of the following surface antigen markers: CD161, CD183, CD223, CD254, CD275, CD45RA, CXCR3, CXCR5, FasL, IL18R1, CTLA-4, OX40, GITR, LAG3, ICOS, PD-1, leu-12, TCR, TLR1, TLR2, TLR3, TLR4, TLR6, NKG2D, CCR, CCR1, CCR2, CCR4, CCR6, and CCR7. The T cells are then contacted with a peptide display library, and target peptides that specifically bind to the T cells are screened therefrom.

The invention provides an anti-PD-1 antibody and an antibody-drug conjugate that binds to CD30 and their use in methods of treating solid tumors. The invention also provides compositions and kits comprising the anti-PD-1 antibody and the antibody-drug conjugate that binds to CD30 for use in treating solid tumors.

A chimeric antigen receptor (CAR) is provided, the CAR comprising a CD30 binding domain comprising a heavy chain complementarity determining region 1 (HCDR1), a heavy chain complementarity determining region 2 (HCDR2), a heavy chain complementarity determining region 3 (HCDR3), a light chain complementarity determining region 1 (LCDRl), a light chain complementarity determining region 2 (LCDR2), and a light chain complementarity determining region 3 (LCDR3), and a hinge region derived from CD28.

Provided is a method for screening polypeptides that specifically target T cells, comprising: providing T cells having a surface antigen marker selected from at least one of CD1, CD2, CD3, CD4, CD5, CD7, CD8, CD16, CD25, CD26, CD27, CD28, CD30, CD38, CD39, CD40L, CD44, CD45, CD62L, CD69, CD73, CD80, CD83, CD86, CD95, CD103, CD119, CD126, CD150, CD152 (CTLA-4), CD153, CD154 (CD40L), CD161, CD183, CD223, CD254, CD275, CD45RA, CXCR3, CXCR5, FasL, IL18R1, CTLA-4, OX40, GITR, LAG3, ICOS, PD-1, leu-12, TCR, TLR1, TLR2, TLR3, TLR4, TLR6, NKG2D, CCR, CCR1, CCR2, CCR4, CCR6, and CCR7; and contacting the T cells with a polypeptide display library, and screening therefrom target polypeptides that specifically bind to the T cells.

Aspects of the present disclosure include improvements to chimeric antigen receptor (CAR) constructs, CAR comprising immune cells, as well as methods for making such constructs and / or cells and methods for their use in treatment of disease (e.g., cancer). Disclosed are immune cells comprising CARs comprising CD30-derived hinge and / or transmembrane and methods for use of such cells in treatment of malignancies (e.g., B-cell malignancies). Also disclosed are polynucleotides encoding a CAR comprising CD30-derived hinge and / or transmembrane domains, as well as cells comprising such polynucleotides and pharmaceutical compositions comprising such cell

The present invention relates to a chimeric antigen receptor including a CD30-derived intracellular signaling domain, immune cells expressing same, and uses thereof. More specifically, the present invention is designed to use a chimeric antigen receptor including a portion of the sequence of TRAF-binding domain within the CD30 domain as an intracellular signaling domain to increase the proliferation and survival of immune effector cells, thereby providing an effect of enhancing antitumor efficacy and cytokine secretion.

The invention relates to the field of biological medicine, and provides a medicine composition for treating tumors and application. The pharmaceutical composition comprises a first active component and a second active component, the first active component comprises a CD30 targeted drug and a pharmaceutically acceptable small molecule compound / salt thereof, the CD30 targeted drug comprises at least one of CD30 CAR-T cells and vibtuximab, and the second active component comprises a pharmaceutically acceptable small molecule compound / salt thereof and a pharmaceutically acceptable small molecule compound / salt thereof, and the CD30 targeted drug comprises at least one of CD30 CAR-T cells and vibtuximab. The second active component comprises a glycosphingolipid synthesis inhibitor and a pharmaceutically acceptable small molecule compound / salt thereof, the glycosphingolipid synthesis inhibitor comprises at least one of eaglukast and meglumine, and the research finds that the combination of the CD30 targeted drug and the glycosphingolipid synthesis inhibitor has a synergistic effect. The invention provides an effective drug combination strategy for tumor treatment, and has a good application prospect in tumor treatment drug selection.

The present disclosure relates to a method of expanding or producing CD56 + / CD3-cells, said method comprising contacting said CD56 + / CD3-cells with an NKp46 agonist and / or a CD30 agonist.

The present invention relates to pharmaceutical compositions comprising multispecific antibodies capable of binding to CD3 and CD30. The invention further provides the use of the pharmaceutical composition for therapeutic and diagnostic procedures, in particular cancer therapy.

The present invention relates to a pharmaceutical composition comprising a multispecific antibody capable of binding to CD3 and CD30. The present invention further provides the use of the pharmaceutical composition for therapeutic and diagnostic procedures, particularly for the treatment of cancer.

The invention relates to a bispecific chimeric antigen receptor (CAR) and application thereof, the CAR comprises a binding domain, and the binding domain comprises a CD30 binding domain and a CD20 binding domain. The invention further relates to an immune cell for expressing the chimeric antigen receptor and application of the immune cell.

The present invention relates, in particular, to T cells expressing a polypeptide-containing chimeric CD95 receptor, wherein the polypeptide comprises at least one CD95-derived polypeptide region having at least 60% sequence identity with a polypeptide domain, polypeptide region, or polypeptide motif of the human CD95 wild-type receptor, the human CD95 polypeptide region comprises a CD95 extracellular ligand-binding domain, and further comprises at least one non-CD95-derived costimulatory cytoplasmic polypeptide domain, region, or motif of tumor necrosis factor receptor superfamily proteins, including CD40, CD40L, CD27, HVEM, GITR, CD30, OX40, and / or LTBR, ​​immunoglobulin superfamily (IgSF) proteins, Toll-like receptors, and / or IL6 receptor family proteins, and the T cells further express the modified T cell receptor.

The invention relates to the technical field of molecular biology and genetic engineering, and discloses sgRNA targeting a chicken CD30 gene and a combination and application thereof. The sgRNA and the sgRNA combination provided by the invention perform targeted knockout on the seventh exon region (transmembrane region) of the chicken CD30 gene, and the sgRNA knockout target of the chicken CD30 is transfected into a chicken fibroblast line DF-1 to prepare the CD30 knockout DF-1 cell, namely the CD30 / -DF-1 cell, and compared with a control group cell through detection, the CD30 expression quantity in the CD30 / -DF-1 cell is extremely low, and the result shows that the CD30 is successfully edited. The establishment of the CD30- / -DF-1 cell line provides an experimental material for deeply researching the functions of CD30.